Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
U.S. FDA Granted Priority Review to Dizal's Sunvozertinib New Drug Application
Details : DZD9008 (sunvozertinib) is an oral, potent, irreversible, & selective EGFR tyrosine kinase inhibitor. It is being evaluated for the treatment of Exon20ins-mutated locally advanced or metastatic NSCLC.
Product Name : DZD9008
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2025
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Burning Rock Dx
Deal Size : Inapplicable
Deal Type : Inapplicable
NMPA Grants Approval For NGS-Based Companion Diagnostic For Lung Cancer
Details :
Product Name : DZD9008
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 10, 2024
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Burning Rock Dx
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
WU-KONG1B Study Shows Sunvozertinib Efficacy in EGFR Exon 20 NSCLC
Details :
Product Name : DZD9008
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 16, 2024
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dizal Submits NDA to FDA for Sunvozertinib in Treating NSCLC with EGFR
Details :
Product Name : DZD9008
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 11, 2024
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Breakthrough Designation to Sunvozertinib for NSCLC Treatment
Details :
Product Name : DZD9008
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 04, 2024
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dizal Highlights Sunvozertinib's Efficacy for Lung Cancer with EGFR Exon 20 Mutations
Details :
Product Name : DZD9008
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2024
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sunvozertinib Meets Primary Endpoint in NSCLC with EGFR Exon 20 Insertions
Details :
Product Name : DZD9008
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 06, 2024
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : DZD9008
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 01, 2023
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Dizal Pharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partnership aims to accelerate the development of DZD9008 (sunvozertinib), an irreversible EGFR inhibitor discovered by Dizal scientists targeting a wide spectrum of EGFR mutations with wild-type EGFR selectivity, for patients with EGFR Exon20ins mut...
Product Name : DZD9008
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 09, 2023
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Dizal Pharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dizal to Demonstrate the Strength and Rapid Acceleration of its Clinical Portfolio at ASCO 2022
Details :
Product Name : DZD9008
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 27, 2022
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable